Skin SACT regimens and guidelines:

The Immuno-Oncology Agent Immune-Related Adverse Event Clinical Guidelines mentioned in the regimen can be accessed on the Chemotherapy page.

Whilst every effort is made to ensure the accuracy of the information in a given regimen it cannot be guaranteed that the regimen is fully up to date, because of the dynamic nature of cancer treatment. Check the regimen details for the specific indication the regimen may be used / funded in. See our disclaimer.

BCC

• Vismodegib

Kaposi’s sarcoma

• Liposomal Doxorubicin

Merkel Cell

• Avelumab
• Carboplatin Etoposide

Sqamous Cell Carcinoma

• Cemiplimab
• Cisplatin Fluorouracil (CF80)

Melanoma Adjuvant

• Dabrafenib Trametinib
• Nivolumab
• Pembrolizumab

Melanoma Metastatic

• Dabrafenib
• Dabrafenib Trametinib
• Dacarbazine
• Encorafenib Binimetinib
• Ipilimumab
• Ipilimumab Nivolumab
• Nivolumab
• Nivolumab and Relatlimab
• Pembrolizumab
• Talimogene laherparepvec
• Vemurafenib

Uveal melanoma

• Tebentafusp

Cisplatin hydration

• Cisplatin hydration

Management guidelines

• Skin cancer management guidelines

SACT regimens written by S Coutts

For further information please contact us using our contact us page.